A tannic extract for oral and topical treatment of CVI and haemorrhoids

P. Rohdewald

doi:10.1055/s-0037-1621484

Phlebologie, Inhaltsverzeichnis

Phlebologie 2015; 44(06): 334-337
DOI: 10.1055/s-0037-1621484

Review Article

Schattauer GmbH

A tannic extract for oral and topical treatment of CVI and haemorrhoids

Artikel in mehreren Sprachen: English | deutsch

P. Rohdewald

¹Institut für Pharmazeutische Chemie, Westfälische-Wilhelms-Universität, Münster, Germany

› Institutsangaben

Abstract

Summary

The present review summarizes investigations concerning the biological activity as well as the clinical actions of an extract from the bark of the French maritime pine, Pycnogenol^®, on the signs and symptoms of the chronic venous insufficiency (CVI). Basis for the anti-oedema and anti-thrombotic action is the maintenance of endothelial health, the capillary sealing, the inhibition of platelet aggregation and the anti-inflammatory and anti-oxidative action of Pycnogenol^® following oral and/or local administration. The improvement of microcirculation contributes to faster healing of ulcers and haemorrhoids. The inhibition of oedema formation of the lower limbs and deep vein thromboses was demonstrated after long haul flights. The comparison with some venotonics and elastic stockings demonstrated superior effects of Pycnogenol^®. Mild unwanted effects were reported with a rate of about 1 %.

Keywords

Pycnogenol^® - oedema - ulcers - thromboses - CVI - haemorrhoids

Volltext

Referenzen

References
1 Rohdewald P. A review of the French maritime pine bark extract (Pycnogenol), a herbal medication with a diverse clinical pharmacology. Int J. Clin Pharmacol Ther 2002; 40 (Suppl. 04) 158-168.
2 Nishioka K, Hidaka T, Nakamura S. et al. Pycnogenol®, French maritime pine bark extract, augments endothelium-dependent vasodilation in humans. Hypertens Res 2007; 30: 775-780.
3 Liu X, Wei J, Tan F. et al. Antidiabetic effect of Pycnogenol® French maritime pine bark extract in patients with diabetes type II. Life Sci 2004; 75 (Suppl. 21) 2505-2513.
4 Cesarone MR, Belcaro G, Rohdewald P. et al. Rapid relief of signs/symptoms in chronic venous microangiopathy with Pycnogenol®: A prospective, controlled study. Angiology 2006; 57 (Suppl. 05) 569-576.
5 Belcaro G, Cesarone MR, Errichi BM. et al. Venous ulcers: Microcirculatory improvement and faster healing with local use of Pycnogenol. Angiology 2005; 56 (Suppl. 06) 699-705.
6 Rohdewald PJ. Pycnogenol®, French Maritime Pine Bark Extract. In: Encyclopedia of Dietary Supplements. Marcel Dekker Inc.; NY: 2005: 545-553.
7 Grimm T, Chovanova Z, Muchova J. et al. Inhibition of NF- B activation and MMP-9 secretion by plasma of human volunteers after ingestion of maritime pine bark extract (Pycnogenol). Journal of Inflammation 2006; 3: 1.
8 Schäfer A, Chovanova Z, Muchova J. et al. Inhibition of Cox-1 and Cox-2 activity by plasma of human volunteers after ingestion of French maritime pine bark extract (Pycnogenol). Biomed Pharmacother 2005; 60 (Suppl. 01) 5-9.
9 Canali R, Comitato R, Schönlau F, Virgili F. The anti-inflammatory pharmacology of Pycnogenol® in humans involves COX-2 and 5-LOX mRNA expression in leukocytes. Int Immunopharmacol 2009; 9: 1145-1149.
10 Lau BHS, Riesen SK, Truong KP. Pycnogenol® as an adjunct in the management of childhood Asthma. J Asthma 2004; 41 (Suppl. 08) 825-832.
11 Grimm T, Schäfer A, Högger P. Antioxidant activity and inhibition of matrix metalloproteinases by metabolites of maritime pine bark extract (Pycnogenol). Free Radic Biol Med 2004; 36 (Suppl. 06) 811-822.
12 Marini A, Grether-Beck S, Jaenicke T. et al. Pycnogenol® effects on skin elasticity and hydration coincide with increased gene expressions of collagen Type I and hyaluronic acid synthase in women. Skin Pharmacol Physiol 2012; 25: 86-92.
13 Gabor M, Engi E, Sonkodi S. Die Kapillarwandresistenz und ihre Beeinflussung durch wasserlösliche Flavonderivate bei spontan hypertonischen Ratten. Phlebologie 1993; 22: 178-182.
14 Belcaro G, Hu S, Cesarone MR, Dugall M. A controlled study shows daily intake of 50mg Pycnogenol significantly lowers plasma reactive oxygen metabolites in 155 healthy smokers. Minerva Med 2013; 104: 439-446.
15 Errichi S, Bottari A, Belcaro G. et al. Supplementation with Pycnogenol® improves signs and symptoms of menopausal transition. Panminerva Med 2011; 53 Suppl. 1, to N°3 65-70.
16 Belcaro G, Dugall M, Luzzi R. et al. Improvement of Venous Tone with Pycnogenol in Chronic Venous Insufficiency: An Ex Vivo Study on Venous Segments. Int J Angiol 2014; 23: 47-52.
17 Schmidtke I, Schoop W. Das hydrostatische Ödem und seine medikamentöse Beeinflussung. Swiss Med 1984; 6 4a 67-69.
18 Arcangeli P. Pycnogenol® in chronic venous insufficiency. Fitoterapia 2000; 71 (Suppl. 03) 236-244.
19 Petrassi C, Mastromarino A, Spartera C. Pycnogenol® in chronic venous insufficiency. Phytomedicine 2000; 7 (Suppl. 05) 383-388.
20 Belcaro G, Cesarone MR, Ricci A. et al. Control of edema in hypertensive subjects treated with calcium antagonist nifedipine) or angiotensin-converting enzyme inhibitors with Pycnogenol. Clin Appl Thromb Hemost 2006; 12 (Suppl. 04) 440-444.
21 Koch R. Comparative study of Venostasin and Pycnogenol in chronic venous insufficiency. Phytother Res 2002; 16: S1-S5.
22 Cesarone MR, Belcaro G, Rohdewald P. et al. Comparison of Pycnogenol and Daflon in Treating Chronic Venous Insufficiency: A prospective, Controlled study. Clin Appl Thromb Hemost 2006; 12 (Suppl. 02) 205-212.
23 Riccioni C, Sarcinella R, Izzo A. et al. Efficacy of Troxerutine in association with Pycnogenol in the treatment of venous insufficiency. Eur Bull Drug Res 2004; 12 (Suppl. 01) 7-12.
24 Belcaro G. A clinical comparison of Pycnogenol, Antistax, and stockings in chronic venous insufficiency. Int J Angiol. 2015 DOI: dx.doi.org/10.1055/s-0035–1556060.
25 Belcaro G, Cesarone MR, Errichi B. et al. Pycnogenol® treatment of acute hemorrhoidal episodes. Phytother Res 2010; 24 (Suppl. 03) 438-444.
26 Belcaro G, Dugall M, Luzzi R. et al. Postpartum varicose veins: Supplementation with Pycnogenol or elastic compression – A 12-month follow-up. Int J Angiol. 2014 DOI 10.1055/s-0033–1363784.
27 Cesarone MR, Belcaro G, Rohdewald P. et al. Improvement of signs and symtpoms of chronic venous insufficiency and microangiopathy with Pycnogenol®: A prospective, controlled study. Phytomedicine 2010; 17: 835-839.
28 Ericchi B, Belcaro G, Hosoi M. et al. Prevention of post-thrombotic syndrome with Pycnogenol®: A 12 month study. Panminerva Med 2011; 53 Suppl. 1, to N°3 21-27.
29 Belcaro G, Cesarone MR, Rohdewald P. et al. Prevention of venous thrombosis and thrombophlebitis in long-haul flights with Pycnogenol. Clin Appl Thromb Hemost 2004; 10 (Suppl. 04) 373-377.
30 Cesarone MR, Belcaro G, Rohdewald P. et al. Prevention of edema in long flights with Pycnogenol®. Clin Appl Thromb Hemost 2005; 11 (Suppl. 03) 289-294.
31 Belcaro G, Cesarone MR, Errichi BM. et al. Diabetic Ulcers: Microcirculatory improvement and faster healing with Pycnogenol. Clin Applied Thromb Hemost 2006; 12 (Suppl. 03) 318-323.
32 Blazso G, Gabor M, Schönlau F, Rohdewald P. Short communication: Pycnogenol® accelerates wound healing and reduces scar formation. Phytother Res 2004; 18 (Suppl. 07) 579-581.
33 Calvo Torras MA, Faura CA, Schönlau F, Rohdewald P. Short Communication: Antimicrobial activity of Pycnogenol®. Phytother Res 2005; 19: 647-648.